Form 4: Beta Bionics Director Granted 3,997 Shares

Sentiment:

Insider Transaction Report


Beta Bionics Director Maria Palasis was granted 3,997 shares of common stock as a restricted stock unit award.

Summary

  • Maria Palasis, a Director of Beta Bionics, Inc. (BBNX), acquired 3,997 shares of common stock.
  • The acquisition occurred on January 13, 2026.
  • These shares were granted as a restricted stock unit award under the company's 2025 Equity Incentive Plan.
  • Following this transaction, Maria Palasis directly beneficially owns 12,432 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of restricted stock units to a director, which is a standard practice for executive compensation and aligns management interests with shareholders. This transaction does not convey significant new operational or financial information.

Positives

  • Director Maria Palasis received a grant of 3,997 shares of common stock, aligning her interests with shareholders.
  • The grant was made under the company's 2025 Equity Incentive Plan, indicating ongoing use of equity compensation to incentivize key personnel.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

  • Director Maria Palasis received a restricted stock unit award from Beta Bionics, Inc. under the company's 2025 Equity Incentive Plan, which is a transaction between a related party (director) and the issuer.

Stakeholder Impact

  • Shareholders: The grant of restricted stock units to a director can enhance alignment between management's interests and long-term shareholder value.

Key Dates

DateDescription
01/13/2026Date of transaction (acquisition of common stock by Maria Palasis).
01/14/2026Date of signature by Stephen Feider, Attorney-in-Fact.

Recommendation

hold

This Form 4 reports a routine grant of restricted stock units to a director, which is a standard compensation practice and does not provide new information to alter the fundamental investment thesis for Beta Bionics, Inc. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Beta Bionics, BBNX, Form 4, insider transaction, stock grant, restricted stock unit, RSU, equity incentive plan, director compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.